Open AccessKEJADIAN MIOKARDITIS PASCA PEMBERIAN VAKSIN COVID-19 BERBASIS mRNA
Author(s) -
Ronald T. H. Tambunan
Publication year - 2021
Publication title -
majalah ilmiah methoda
Language(s) - English
Resource type - Journals
eISSN - 2656-6931
pISSN - 2088-9534
DOI - 10.46880/methoda.vol11no3.pp176-184
Subject(s) - vaccination , myocarditis , medicine , covid-19 , pandemic , adverse effect , viral myocarditis , mortality rate , messenger rna , immunology , intensive care medicine , disease , biology , biochemistry , infectious disease (medical specialty) , gene
COVID-19 is still being a pandemic with high morbidity and mortality rate. In Indonesia, there were about 4 million cases with 150 thousand of them ending up in death. The approved COVID-19 vaccines have been successful in decreasing their morbidity and mortality rate, with mRNA-based vaccines such as BNT162b2 and mRNA-1273 having high efficacy. There are reports about the post-vaccination adverse events such as myocarditis, therefore a literature review was written about the problem. This article was made as a literature review, collecting previous research articles about myocarditis induced by the mRNA COVID-19 vaccine. Data collecting was done subjectively, without using any structured planning systematic and narratively presented. There are seven research articles investigating post-vaccination myocarditis, which 5 of them concluded about an increased risk of myocarditis event due to mRNA vaccine, one article stated that mRNA vaccine whether it is BNT162b2 or mRNA-1273, is safe to be used, and one article stated there is no correlation between myocarditis and mRNA vaccination due to a very small incident rate. mRNA COVID-19 vaccines are safe to be used due to their high efficacy in preventing severe clinical manifestations of SARS-CoV-2 infection. A post-vaccination adverse event like myocarditis is very rare and has a temporary and mild clinical manifestation in nature.